Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
426 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06467357 | Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer(DESTINY-BTC01) | recruiting | Phase 3 | 620 | AstraZenecaINDUSTRY | 27 | Aug 19, 2026 | clinicaltrials |
| NCT04546009 | A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) | active not recruiting | Phase 3 | 992 | Hoffmann-La RocheINDUSTRY |
| 30 |
| Aug 17, 2026 |
| clinicaltrials |
| NCT04862663 | Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)(CAPItello-292) | active not recruiting | Phase 3 | 893 | AstraZenecaINDUSTRY | 23 | Aug 17, 2026 | clinicaltrials |
| NCT03847428 | Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment(EMERALD-2) | active not recruiting | Phase 3 | 908 | AstraZenecaINDUSTRY | 24 | Aug 14, 2026 | clinicaltrials |
| NCT04736706 | A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) | active not recruiting | Phase 3 | 1,854 | Merck Sharp & Dohme LLCINDUSTRY | 35 | Aug 14, 2026 | clinicaltrials |
| NCT06074588 | Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) | active not recruiting | Phase 3 | 556 | Merck Sharp & Dohme LLCINDUSTRY | 25 | Aug 14, 2026 | clinicaltrials |
| NCT06149286 | A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma(OLYMPIA-5) | recruiting | Phase 3 | 580 | Regeneron PharmaceuticalsINDUSTRY | 18 | Aug 14, 2026 | clinicaltrials |
| NCT04603807 | A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases | active not recruiting | Phase 3 | 217 | Hoffmann-La RocheINDUSTRY | 18 | Aug 13, 2026 | clinicaltrials |
| NCT06016738 | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer(OPERA-01) | active not recruiting | Phase 3 | 510 | Olema Pharmaceuticals, Inc.INDUSTRY | 26 | Aug 13, 2026 | clinicaltrials |
| NCT05113251 | Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer | active not recruiting | Phase 3 | 927 | AstraZenecaINDUSTRY | 18 | Aug 11, 2026 | clinicaltrials |
| NCT05303532 | Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab(ROSY-D) | enrolling by invitation | Phase 3 | 214 | AstraZenecaINDUSTRY | 31 | Aug 11, 2026 | clinicaltrials |
| NCT05952557 | An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)(CAMBRIA-2) | active not recruiting | Phase 3 | 5,511 | AstraZenecaINDUSTRY | 44 | Aug 10, 2026 | clinicaltrials |
| NCT06731478 | Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer | recruiting | Phase 3 | 726 | Daiichi SankyoINDUSTRY | 26 | Aug 10, 2026 | clinicaltrials |
| NCT02453282 | Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)(MYSTIC) | active not recruiting | Phase 3 | 1,118 | AstraZenecaINDUSTRY | 17 | Aug 6, 2026 | clinicaltrials |
| NCT05261399 | Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment(SAFFRON) | active not recruiting | Phase 3 | 341 | AstraZenecaINDUSTRY | 27 | Aug 6, 2026 | clinicaltrials |
| NCT05170204 | A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)(HORIZON 1) | active not recruiting | Phase 3 | 68 | Hoffmann-La RocheINDUSTRY | 19 | Aug 5, 2026 | clinicaltrials |
| NCT05171647 | A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma(SUNMO) | active not recruiting | Phase 3 | 208 | Hoffmann-La RocheINDUSTRY | 13 | Aug 5, 2026 | clinicaltrials |
| NCT03521154 | A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)(LAURA) | active not recruiting | Phase 3 | 216 | AstraZenecaINDUSTRY | 17 | Aug 4, 2026 | clinicaltrials |
| NCT05973773 | REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)(REZILIENT3) | active not recruiting | Phase 3 | 285 | Taiho Oncology, Inc.INDUSTRY | 23 | Jul 30, 2026 | clinicaltrials |
| NCT05678673 | Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma(STELLAR-304) | active not recruiting | Phase 3 | 317 | ExelixisINDUSTRY | 25 | Jul 29, 2026 | clinicaltrials |
| NCT06120491 | Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents(EvoPAR-PR01) | active not recruiting | Phase 3 | 1,898 | AstraZenecaINDUSTRY | 24 | Jul 29, 2026 | clinicaltrials |
| NCT05984277 | A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.(eVOLVE-Lung02) | active not recruiting | Phase 3 | 895 | AstraZenecaINDUSTRY | 25 | Jul 28, 2026 | clinicaltrials |
| NCT03298451 | Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma(HIMALAYA) | active not recruiting | Phase 3 | 1,324 | AstraZenecaINDUSTRY | 17 | Jul 27, 2026 | clinicaltrials |
| NCT03768063 | A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study(IMbrella B) | active not recruiting | Phase 3 | 1,000 | Hoffmann-La RocheINDUSTRY | 24 | Jul 24, 2026 | clinicaltrials |
| NCT03924856 | Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)(KEYNOTE-866) | completed | Phase 3 | 907 | Merck Sharp & Dohme LLCINDUSTRY | 22 | Jul 22, 2026 | clinicaltrials |
| NCT07720284 | An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC(TU-04) | recruiting | Phase 3 | 915 | AstraZenecaINDUSTRY | 16 | Jul 22, 2026 | clinicaltrials |
| NCT07218809 | AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer(TREVI-OC-01) | recruiting | Phase 3 | 1,100 | AstraZenecaINDUSTRY | 24 | Jul 21, 2026 | clinicaltrials |
| NCT05425940 | Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer(STELLAR-303) | active not recruiting | Phase 3 | 901 | ExelixisINDUSTRY | 16 | Jul 17, 2026 | clinicaltrials |
| NCT07710885 | Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer(FOENIX-BTC) | recruiting | Phase 3 | 784 | Taiho Pharmaceutical Co., Ltd.INDUSTRY | 4 | Jul 17, 2026 | clinicaltrials |
| NCT03456076 | A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer | active not recruiting | Phase 3 | 257 | Hoffmann-La RocheINDUSTRY | 27 | Jul 15, 2026 | clinicaltrials |
| NCT03778957 | A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma(EMERALD-1) | active not recruiting | Phase 3 | 724 | AstraZenecaINDUSTRY | 18 | Jul 15, 2026 | clinicaltrials |
| NCT05800015 | A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer | active not recruiting | Phase 2 / Phase 3 | 160 | Regeneron PharmaceuticalsINDUSTRY | 10 | Jul 15, 2026 | clinicaltrials |
| NCT03519971 | Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer | completed | Phase 3 | 328 | AstraZenecaINDUSTRY | 14 | Jul 14, 2026 | clinicaltrials |
| NCT05301842 | Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC(EMERALD-3) | active not recruiting | Phase 3 | 760 | AstraZenecaINDUSTRY | 22 | Jul 13, 2026 | clinicaltrials |
| NCT06112379 | A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer | active not recruiting | Phase 3 | 1,902 | AstraZenecaINDUSTRY | 26 | Jul 13, 2026 | clinicaltrials |
| NCT03148418 | A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A) | active not recruiting | Phase 3 | 382 | Hoffmann-La RocheINDUSTRY | 32 | Jul 10, 2026 | clinicaltrials |
| NCT06109779 | Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) | active not recruiting | Phase 3 | 760 | AstraZenecaINDUSTRY | 21 | Jul 10, 2026 | clinicaltrials |
| NCT06346392 | AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 | active not recruiting | Phase 3 | 594 | AstraZenecaINDUSTRY | 19 | Jul 9, 2026 | clinicaltrials |
| NCT06348199 | A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer | active not recruiting | Phase 3 | 555 | Samsung Bioepis Co., Ltd.INDUSTRY | 14 | Jul 7, 2026 | clinicaltrials |
| NCT05120349 | A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection(ADAURA2) | active not recruiting | Phase 3 | 390 | AstraZenecaINDUSTRY | 20 | Jul 6, 2026 | clinicaltrials |
| NCT06356129 | Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma(GOLSEEK-1) | active not recruiting | Phase 3 | 850 | CelgeneINDUSTRY | 38 | Jul 6, 2026 | clinicaltrials |
| NCT05785767 | A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) | active not recruiting | Phase 2 / Phase 3 | 149 | Regeneron PharmaceuticalsINDUSTRY | 11 | Jul 2, 2026 | clinicaltrials |
| NCT04064060 | A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials | recruiting | Phase 3 | 665 | CelgeneINDUSTRY | 22 | Jul 1, 2026 | clinicaltrials |
| NCT04655976 | Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy(COSTAR Lung) | active not recruiting | Phase 2 / Phase 3 | 758 | GlaxoSmithKlineINDUSTRY | 24 | Jul 1, 2026 | clinicaltrials |
| NCT04248829 | Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301) | completed | Phase 3 | 393 | Yuhan CorporationINDUSTRY | 13 | Jun 29, 2026 | clinicaltrials |
| NCT03088540 | Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 3 | 712 | Regeneron PharmaceuticalsINDUSTRY | 24 | Jun 25, 2026 | clinicaltrials |
| NCT05555732 | Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) | active not recruiting | Phase 3 | 1,170 | Daiichi SankyoINDUSTRY | 29 | Jun 23, 2026 | clinicaltrials |
| NCT04102098 | A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation(IMbrave050) | completed | Phase 3 | 668 | Hoffmann-La RocheINDUSTRY | 26 | Jun 18, 2026 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials